Jacob Gottlieb’s New Company Altium Looking To Change Diabetes Management
Jacob Gottlieb is getting back into the world of hedge funds after finishing up the liquidation process with his old firm Visium. Stuck in the middle of a scandal that involved insider-trading, Jacob Gottlieb didn’t want to give up on the world of investing because of someone else’s mistakes and bad decisions. The new fund he is working on involves a former business partner Stuart Weisbrod. While the 2 have been apart for 2 decades, they are already making the moves to once again work under the same roof.
The 2 worked together at Merlin, a company that was co-founded by Weisbrod in 1998. merlin largely focused on the healthcare sector and Jacob Gottlieb primarily plans to focus most of their new fund in a similar area. After all, the 2 both have extensive experience in the field so it seems natural to go with what they already know.
In 2000, Jacob Gottlieb began working for Merlin as a portfolio manager. During the height of the biotech revolution, Merlin saw 100% returns on their investments among. Due to this success, Jacob Gottlieb and other portfolio managers were able to attract some impressive clients to the company such as major pension funds and family offices.
The new hedge fund from Jacob Gottlieb is going to be called Altium Capital. While he is still busy performing the final acts in winding down his old company, he has a lot of hope for his investing future. The scandal that rocked Visium was found to involve only a small group of employees and Jacob Gottlieb was cleared of all charges as he was not aware of what had been occurring at the time.
Jacob Gottlieb is already investing in an impressive product that will allow diabetic patients to take their insulin orally as opposed to injection. For years, scientists and doctors have been trying to find ways to allow insulin to remain effective when ingested orally to no avail. This new capsule shows a lot of promise and is expected to help reduce the number of infections related with taking insulin through a syringe or pump.